Incidence of contrast-induced nephropathy in hospitalised patients with cancer

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidGülşen, Emrah/HHY-9633-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorCicin, Irfan
dc.contributor.authorErdogan, Bulent
dc.contributor.authorGulsen, Emrah
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorSut, Necdet
dc.contributor.authorTurkmen, Esma
dc.contributor.authorKodaz, Hilmi
dc.date.accessioned2024-06-12T10:58:25Z
dc.date.available2024-06-12T10:58:25Z
dc.date.issued2014
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer. Methods Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline. Relationships between CIN and possible risk factors were investigated. Results CIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P=0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P=0.005); it was also an independent risk factor (P=0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P=0.021) and in patients with hypertension (P=0.044). Conclusions The incidence of CIN after CT in hospitalised oncological patients was 20 %. CIN developed 4.5-times more frequently in patients with cancer who had undergone recent chemotherapy. Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development. Key Points Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. CIN occurs more often when CT is performed <45 days after chemotherapy. Hypertension and treatment with bevacizumab appear to be additional risk factors.en_US
dc.identifier.doi10.1007/s00330-013-2996-6
dc.identifier.endpage190en_US
dc.identifier.issn0938-7994
dc.identifier.issn1432-1084
dc.identifier.issue1en_US
dc.identifier.pmid24220752en_US
dc.identifier.scopus2-s2.0-84890411322en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage184en_US
dc.identifier.urihttps://doi.org/10.1007/s00330-013-2996-6
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20066
dc.identifier.volume24en_US
dc.identifier.wosWOS:000328337800024en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Radiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectContrast-Induced Nephropathyen_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectBevacizumaben_US
dc.subjectMedia-Induced Nephrotoxicityen_US
dc.subjectAcute-Renal-Failureen_US
dc.subjectInsufficiencyen_US
dc.subjectKidneyen_US
dc.subjectMedullaryen_US
dc.subjectIodixanolen_US
dc.subjectViscosityen_US
dc.subjectAgentsen_US
dc.titleIncidence of contrast-induced nephropathy in hospitalised patients with canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu